NCT06538012 - TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

September 10, 2026

Study Completion Date

December 28, 2026

Conditions

Lung CancerLung Cancer MetastaticLung Cancer, Non-small CellLung Cancer Recurrent

Interventions

BIOLOGICAL

Tumor Infiltrating Lymphocytes (TIL)

Tumor Infiltrating Lymphocytes (TIL) IV

DRUG

Cyclophosphamide

Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

DRUG

Fludarabine

Fludarabine will be administered as an intravenous (IV) infusion for five days.

DRUG

Interleukin-2

After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.

DRUG

Pembrolizumab

Intravenous (IV) infusion

Trial Locations (1)

RECRUITING

District One Hospital, Beijing